Bridging the Needs of Security and Development Teams, Veracode Unveils Next-Generation Software Security Platform
4.5.2022 15:12:00 EEST | Business Wire | Press release
Veracode, a leading global provider of application security testing (AST) solutions, today announced its Continuous Software Security Platform, which seamlessly embeds application security into the software development lifecycle (SDLC). The platform streamlines workflows by bringing together development and security teams to provide a broad understanding of risk, remediation guidance, and progress at every stage of the development process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005671/en/
Fig. 1 The Veracode Continuous Software Security Platform (Graphic: Business Wire)
According to Veracode’s latest research, there has been a 20x increase in average scan cadence over the past decade, with most applications tested three times per week, as opposed to three times per year a decade ago. The research also showed a 31 percent increase in organizations using multiple scan types over the last three years alone.
Today, leading organizations recognize the need to leverage multiple methods to assess their software and do so across all stages of the development lifecycle. Gartner® predicts that “by 2025, 70% of organizations will consolidate the number of vendors securing the lifecycle of cloud-native applications to a maximum of three vendors.” ¹ This suggests companies are already looking for a comprehensive platform that provides flexible policy management, a holistic assessment of software risk, and integrated remediation guidance, while simplifying the complexity of managing multiple solutions.
Pervasive but Not Invasive for Developers
With increased pressure to build and deploy software at breakneck speed, development teams require security checks to be seamlessly integrated into the tools where they work so they can find and fix vulnerabilities quickly. Meanwhile, security teams must meet increasingly stringent compliance standards defined by their boards and regulatory bodies. Veracode’s Continuous Software Security Platform is pervasive but not invasive because it provides a frictionless experience for developers by embedding vulnerability analysis with remediation guidance directly into the integrated development environment.
Brian Roche, Chief Product Officer at Veracode, said, “Other vendors in our space have incomplete or disjointed solutions that lack consistent reporting and analysis, leaving customers playing a game of ‘whack a mole’ across different tools. We have continued to evolve our platform to create a seamless and integrated experience for developers, as well as provide security teams with a holistic view of their software security posture from design, through development and deployment. We see this as a win for both development and security teams that will result in the delivery of software that is more secure.”
Veracode Continuous Software Security Platform
The Veracode Continuous Software Security Platform enables users to define and manage security policy, gain a comprehensive view of software security across their application portfolio, and leverage rich analytics to make informed plans, communicate metrics, comply with policy, and meet regulatory requirements. Powered by almost two decades of data, the platform enables organizations to detect, predict, manage, and, ultimately, mitigate their security risk. These intelligent capabilities empower companies to deliver secure code at the speed and scale expected in today’s world.
The new Veracode Continuous Software Security Platform release features several new capabilities including:
- Single-Pane-of-Glass Reporting: Security teams can now access unified reporting directly in the portal for Static Analysis, Dynamic Analysis, Software Composition Analysis, and Manual Penetration Testing. Administrators and developers now have a consolidated view into security risks, as well as flexible policy controls through stronger license management reports to address issues quickly.
- Self-Service Peer Benchmarking: With comprehensive data and anonymized insights across all platform users, customers now have direct access to reports on the portal, which enable them to easily benchmark their DevSecOps program results against others in their industry. Tapping into many years of data and learning, customers can see how their program metrics stack up and establish plans to address their risk.
- Software Bill of Materials (SBOM): Security teams can now generate and export SBOMs on demand with an integrated representational state transfer (REST) API. This returns data for a specific application in CycloneDX SBOM format—a standard designed for use in application security contexts and supply chain component analysis. Additionally, data from the API can be mined and transformed outside of the Veracode Platform.
- Intelligent Remediation: The Continuous Software Security Platform will leverage technology acquired from Jaroona to detect and remediate software vulnerabilities through machine learning. Jaroona, which was recognized by Gartner Research as a “Cool Vendor” in 2021, outperforms traditional approaches by 7x to 10x in terms of accuracy, false negatives, and false positive rates, and reduces the burden on technical resources.
According to Tabrez Naqvi, Director of Information Security and Risk at Cox Automotive, “The security of our products and services is very important to us, and Veracode helps us ensure that we never lose our customers' trust and confidence."
For more information on the Veracode Continuous Software Security Platform visit https://www.veracode.com/platform.
¹Gartner, Inc. ”Predicts 2022: Consolidated Security Platforms Are the Future” by Charlie Winckless, Joerg Fritsch, Peter Firstbrook, Neil MacDonald, Brian Lowans, 1 December 2021
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.
Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005671/en/
Contact information
For more information, please contact:
Katy Gwilliam
kgwilliam@veracode.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen. According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances. IDE034 is a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and lice
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 10:15:00 EET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 09:18:00 EET | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers compared to currently available technologies. This in turn is boosting expectations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
